Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M. & Wallace, M. B. Colorectal most cancers. Lancet 394, 1467–1480 (2019).
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A. & Jemal, A. Colorectal most cancers statistics, 2023. CA Most cancers J. Clin. 73, 233–254 (2023).
Douillard, J.-Y. et al. Panitumumab–FOLFOX4 remedy and RAS mutations in colorectal most cancers. N. Engl. J. Med. 369, 1023–1034 (2013).
Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal most cancers. N. Engl. J. Med. 350, 2335–2342 (2004).
Cervantes, A. et al. Metastatic colorectal most cancers: ESMO Scientific Apply Guideline for prognosis, remedy and follow-up. Ann. Oncol. 34, 10–32 (2022).
Brahmer, J. R. et al. Security and exercise of anti-PD-L1 antibody in sufferers with superior most cancers. N. Engl. J. Med. 366, 2455–2465 (2012).
Topalian, S. L. et al. Security, exercise, and immune correlates of anti-PD-1 antibody in most cancers. N. Engl. J. Med. 366, 2443–2454 (2012).
Fearon, E. R. & Vogelstein, B. A genetic mannequin for colorectal tumorigenesis. Cell 61, 759–767 (1990).
Lannagan, T. R., Jackstadt, R., Leedham, S. J. & Sansom, O. J. Advances in colon most cancers analysis: in vitro and animal fashions. Curr. Opin. Genet. Dev. 66, 50–56 (2021).
Batlle, E. & Clevers, H. Most cancers stem cells revisited. Nat. Med. 23, 1124–1134 (2017).
Tilg, H., Adolph, T. E., Gerner, R. R. & Moschen, A. R. The intestinal microbiota in colorectal most cancers. Most cancers Cell 33, 954–964 (2018).
Kuipers, E. J. et al. Colorectal most cancers. Nat. Rev. Dis. Prim. 1, 15065 (2015).
Li, J., Ma, X., Chakravarti, D., Shalapour, S. & DePinho, R. A. Genetic and organic hallmarks of colorectal most cancers. Genes. Dev. 38, 787–820 (2021).
Rahbari, N. N. et al. Time of metastasis and consequence in colorectal most cancers. Ann. Surg. 269, 494–502 (2019).
Chen, Ok., Collins, G., Wang, H. & Toh, J. W. T. Pathological options and prognostication in colorectal most cancers. Curr. Oncol. 28, 5356–5383 (2021).
Gustavsson, B. et al. A assessment of the evolution of systemic chemotherapy within the administration of colorectal most cancers. Clin. Colorectal Most cancers 14, 1–10 (2015).
Kopetz, S. et al. Improved survival in metastatic colorectal most cancers is related to adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 27, 3677–3683 (2009).
Pastorino, U. et al. Lengthy-term outcomes of lung metastasectomy: prognostic analyses primarily based on 5206 instances. J. Thorac. Cardiovasc. Surg. 113, 37–49 (1997).
Lipsyc, M. & Yaeger, R. Impression of somatic mutations on patterns of metastasis in colorectal most cancers. J. Gastrointest. Oncol. 6, 645–649 (2015).
Yaeger, R. et al. Scientific sequencing defines the genomic panorama of metastatic colorectal most cancers. Most cancers Cell 33, 125–136.e3 (2018).
Moertel, C. G. et al. Levamisole and fluorouracil for adjuvant remedy of resected colon carcinoma. N. Engl. J. Med. 322, 352–358 (1990).
Varghese, A. Chemotherapy for stage II colon most cancers. Clin. Colon. Rectal Surg. 28, 256–261 (2015).
André, T. et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon most cancers: up to date 10-year survival and outcomes based on BRAF mutation and mismatch restore standing of the MOSAIC examine. J. Clin. Oncol. 33, 4176–4187 (2015).
Tie, J. et al. Circulating tumor DNA evaluation guiding adjuvant remedy in stage II colon most cancers. N. Engl. J. Med. 386, 2261–2272 (2022).
Kotani, D. et al. Molecular residual illness and efficacy of adjuvant chemotherapy in sufferers with colorectal most cancers. Nat. Med. 29, 127–134 (2023).
Birkbak, N. J. & McGranahan, N. Most cancers genome evolutionary trajectories in metastasis. Most cancers Cell 37, 8–19 (2020).
Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic strong tumours. Nature 575, 210–216 (2019).
Robinson, D. R. et al. Integrative scientific genomics of metastatic most cancers. Nature 548, 297–303 (2017).
Zehir, A. et al. Mutational panorama of metastatic most cancers revealed from potential scientific sequencing of 10,000 sufferers. Nat. Med. 23, 703–713 (2017).
Martínez-Jiménez, F. et al. Pan-cancer whole-genome comparability of major and metastatic strong tumours. Nature 618, 333–341 (2023).
Nguyen, B. et al. Genomic characterization of metastatic patterns from potential scientific sequencing of 25,000 sufferers. Cell 185, 563–575.e11 (2022).
Sottoriva, A. et al. A Huge Bang mannequin of human colorectal tumor development. Nat. Genet. 47, 209–216 (2015).
Holch, J. W., Ricard, I., Stintzing, S., Modest, D. P. & Heinemann, V. The relevance of major tumour location in sufferers with metastatic colorectal most cancers: a meta-analysis of first-line scientific trials. Eur. J. Most cancers 70, 87–98 (2017).
Sartore-Bianchi, A. et al. Central nervous system as doable website of relapse in ERBB2-positive metastatic colorectal most cancers. JAMA Oncol. 6, 927 (2020).
Strickler, J. H., Yoshino, T., Graham, R. P., Siena, S. & Bekaii-Saab, T. Prognosis and remedy of ERBB2-positive metastatic colorectal most cancers. JAMA Oncol. 8, 760 (2022).
Schell, M. J. et al. A multigene mutation classification of 468 colorectal cancers reveals a prognostic function for APC. Nat. Commun. 7, 1–12 (2016).
Elez, E. et al. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal most cancers. Nat. Med. 28, 2162–2170 (2022).
Parsons, M. J., Tammela, T. & Dow, L. E. WNT as a driver and dependency in most cancers. Most cancers Discov. 11, 2413–2429 (2021).
Muzny, D. M. et al. Complete molecular characterization of human colon and rectal most cancers. Nature 487, 330–337 (2012).
Fujii, M. et al. A colorectal tumor organoid library demonstrates progressive lack of area of interest issue necessities throughout tumorigenesis. Cell Stem Cell 18, 827–838 (2016).
Fumagalli, A. et al. Genetic dissection of colorectal most cancers development by orthotopic transplantation of engineered most cancers organoids. Proc. Natl Acad. Sci. USA 114, E2357–E2364 (2017).
Sato, T. et al. Single Lgr5 stem cells construct crypt-villus buildings in vitro with out a mesenchymal area of interest. Nature 459, 262–265 (2009).
Jung, P. et al. Isolation and in vitro enlargement of human colonic stem cells. Nat. Med. 17, 1225–1227 (2011).
Van De Wetering, M. et al. Potential derivation of a dwelling organoid biobank of colorectal most cancers sufferers. Cell 161, 933–945 (2015).
Matano, M. et al. Modeling colorectal most cancers utilizing CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21, 256–262 (2015).
O’Rourke, Ok. P. et al. Transplantation of engineered organoids allows fast technology of metastatic mouse fashions of colorectal most cancers. Nat. Biotechnol. 35, 577–582 (2017).
Tauriello, D. V. F. et al. TGFβ drives immune evasion in genetically reconstituted colon most cancers metastasis. Nature 554, 538–543 (2018).
Roper, J. et al. In vivo genome enhancing and organoid transplantation fashions of colorectal most cancers and metastasis. Nat. Biotechnol. 35, 569–576 (2017).
Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer evaluation of clonality and the timing of systemic unfold in paired major tumors and metastases. Nat. Genet. 52, 701–708 (2020).
Roerink, S. F. et al. Intra-tumour diversification in colorectal most cancers on the single-cell stage. Nature 556, 457–462 (2018).
Hu, Z. et al. Quantitative proof for early metastatic seeding in colorectal most cancers. Nat. Genet. 51, 1113–1122 (2019).
Naxerova, Ok. et al. Origins of lymphatic and distant metastases in human colorectal most cancers. Science 357, 55–60 (2017).
Reiter, J. G. et al. Lymph node metastases develop by a wider evolutionary bottleneck than distant metastases. Nat. Genet. 52, 692–700 (2020).
Ryser, M. D., Min, B. H., Siegmund, Ok. D. & Shibata, D. Spatial mutation patterns as markers of early colorectal tumor cell mobility. Proc. Natl Acad. Sci. USA 115, 5774–5779 (2018).
Bretthauer, M. et al. Impact of colonoscopy screening on dangers of colorectal most cancers and associated dying. N. Engl. J. Med. 387, 1547–1556 (2022).
Dang, H. X. et al. The clonal evolution of metastatic colorectal most cancers. Sci. Adv. 6, eaay9691 (2020).
Kok, S. Y. et al. Malignant subclone drives metastasis of genetically and phenotypically heterogenous cell clusters by fibrotic area of interest technology. Nat. Commun. 12, 863 (2021).
Cheung, Ok. J. & Ewald, A. J. A collective path to metastasis: seeding by tumor cell clusters. Science 352, 167–169 (2016).
Comen, E., Norton, L. & Massagué, J. Scientific implications of most cancers self-seeding. Nat. Rev. Clin. Oncol. 8, 369–377 (2011).
Campbell, Ok. et al. Collective cell migration and metastases induced by an epithelial-to-mesenchymal transition in Drosophila intestinal tumors. Nat. Commun. 10, 2311 (2019).
Cañellas-Socias, A. et al. Metastatic recurrence in colorectal most cancers arises from residual EMP1+ cells. Nature 611, 603–613 (2022).
Massagué, J. & Ganesh, Ok. Metastasis-initiating cells and ecosystems. Most cancers Discov. 11, 971–994 (2021).
André, T. et al. Improved general survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant remedy in stage II or III colon most cancers within the MOSAIC trial. J. Clin. Oncol. 27, 3109–3116 (2009).
Nors, J., Iversen, L. H., Erichsen, R., Gotschalck, Ok. A. & Andersen, C. L. Incidence of recurrence and time to recurrence in stage I to III colorectal most cancers. JAMA Oncol. 10, 54–62 (2024).
Engstrand, J., Strömberg, C., Nilsson, H., Freedman, J. & Jonas, E. Synchronous and metachronous liver metastases in sufferers with colorectal most cancers – in direction of a clinically related definition. World J. Surg. Oncol. 17, 228 (2019).
Mizuno, T. et al. SMAD4 gene mutation predicts poor prognosis in sufferers present process resection for colorectal liver metastases. Eur. J. Surg. Oncol. 44, 684–692 (2018).
Álvarez-Varela, A. et al. Mex3a marks drug-tolerant persister colorectal most cancers cells that mediate relapse after chemotherapy. Nat. Most cancers 3, 1052–1070 (2022).
Gerstberger, S., Jiang, Q. & Ganesh, Ok. Metastasis. Cell 186, 1564–1579 (2023).
Smith, H. A. & Kang, Y. Determinants of organotropic metastasis. Annu. Rev. Most cancers Biol. 1, 403–423 (2017).
Font-Clos, F., Zapperi, S. & La Porta, C. A. M. Blood stream contributions to most cancers metastasis. iScience 23, 101073 (2020).
Denève, E. et al. Seize of viable circulating tumor cells within the liver of colorectal most cancers sufferers. Clin. Chem. 59, 1384–1392 (2013).
Tsilimigras, D. I. et al. Liver metastases. Nat. Rev. Dis. Prim. 7, 27 (2021).
Riihimaki, M., Hemminki, A., Sundquist, J. & Hemminki, Ok. Patterns of metastasis in colon and rectal most cancers. Sci. Rep. 6, 29765 (2016).
Wei, Q. et al. Multiregion whole-exome sequencing of matched major and metastatic tumors revealed genomic heterogeneity and instructed polyclonal seeding in colorectal most cancers metastasis. Ann. Oncol. 28, 2135–2141 (2017).
Gassmann, P., Hemping-Bovenkerk, A., Mees, S. T. & Haier, J. Metastatic tumor cell arrest within the liver-lumen occlusion and particular adhesion will not be unique. Int. J. Colorectal Dis. 24, 851–858 (2009).
Haier, J., Korb, T., Hotz, B., Spiegel, H.-U. & Senninger, N. An intravital mannequin to watch steps of metastatic tumor cell adhesion inside the hepatic microcirculation. J. Gastrointest. Surg. 7, 507–515 (2003).
Brodt, P. et al. Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int. J. Most cancers 71, 612–619 (1997).
Khatib, A.-M., Fallavollita, L., Wancewicz, E. V., Monia, B. P. & Brodt, P. Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. Most cancers Res. 62, 5393–5398 (2002).
Nakamori, S. et al. Involvement of carbohydrate antigen sialyl Lewisx in colorectal most cancers metastasis. Dis. Colon. Rectum 40, 420–431 (1997).
Timmers, M. et al. Interactions between rat colon carcinoma cells and Kupffer cells through the onset of hepatic metastasis. Int. J. Most cancers 112, 793–802 (2004).
Matsumura, H. et al. Kupffer cells lower metastasis of colon most cancers cells to the liver within the early stage. Int. J. Oncol. 45, 2303–2310 (2014).
Urosevic, J. et al. Colon most cancers cells colonize the lung from established liver metastases by p38 MAPK signalling and PTHLH. Nat. Cell Biol. 16, 685–694 (2014).
Sonoshita, M. et al. Promotion of colorectal most cancers invasion and metastasis by activation of NOTCH–DAB1–ABL–RHOGEF protein TRIO. Most cancers Discov. 5, 198–211 (2015).
Sonoshita, M. et al. Suppression of colon most cancers metastasis by Aes by inhibition of Notch signaling. Most cancers Cell 19, 125–137 (2011).
Giannou, A. D. et al. Tissue resident iNKT17 cells facilitate most cancers cell extravasation in liver metastasis through interleukin-22. Immunity 56, 125–142.e12 (2023).
Franko, J. et al. Therapy of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled evaluation of north central most cancers remedy group part III trials N9741 and N9841. J. Clin. Oncol. 30, 263–267 (2012).
Franko, J. et al. Prognosis of sufferers with peritoneal metastatic colorectal most cancers given systemic remedy: an evaluation of particular person affected person information from potential randomised trials from the Evaluation and Analysis in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 17, 1709–1719 (2016).
Bootsma, S., Bijlsma, M. F. & Vermeulen, L. The molecular biology of peritoneal metastatic illness. EMBO Mol. Med. 15, e15914 (2023).
Enblad, M., Graf, W. & Birgisson, H. Threat components for appendiceal and colorectal peritoneal metastases. Eur. J. Surg. Oncol. 44, 997–1005 (2018).
Demuytere, J., Ernst, S., van Ovost, J., Cosyns, S. & Ceelen, W. The tumor immune microenvironment in peritoneal carcinomatosis. Int. Rev. Cell Mol. Biol. 371, 63–95 (2022).
Lenos, Ok. J. et al. Molecular characterization of colorectal most cancers associated peritoneal metastatic illness. Nat. Commun. 13, 4443 (2022).
Laoukili, J. et al. Peritoneal metastases from colorectal most cancers belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting lowering capability. Br. J. Most cancers 126, 1824–1833 (2022).
Househam, J. et al. Phenotypic plasticity and genetic management in colorectal most cancers evolution. Nature 611, 744–753 (2022).
Joanito, I. et al. Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal most cancers. Nat. Genet. 54, 963–975 (2022).
Vermeulen, L. et al. Wnt exercise defines colon most cancers stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468–476 (2010).
Lenos, Ok. J. et al. Stem cell performance is microenvironmentally outlined throughout tumour enlargement and remedy response in colon most cancers. Nat. Cell Biol. 20, 1193–1202 (2018).
Medema, J. P. & Vermeulen, L. Microenvironmental regulation of stem cells in intestinal homeostasis and most cancers. Nature 474, 318–326 (2011).
De Sousa e Melo, F. et al. A definite function for Lgr5+ stem cells in major and metastatic colon most cancers. Nature 543, 676–680 (2017).
Fumagalli, A. et al. Plasticity of Lgr5-negative most cancers cells drives metastasis in colorectal most cancers. Cell Stem Cell 26, 569–578.e7 (2020).
Heinz, M. C. et al. Liver colonization by colorectal most cancers metastases requires YAP-controlled plasticity on the micrometastatic stage. Most cancers Res. 82, 1953–1968 (2022).
Ganesh, Ok. et al. L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal most cancers. Nat. Most cancers 1, 28–45 (2020).
Barker, N. et al. Identification of stem cells in small gut and colon by marker gene Lgr5. Nature 449, 1003–1007 (2007).
Ayyaz, A. et al. Single-cell transcriptomes of the regenerating gut reveal a revival stem cell. Nature 569, 121–125 (2019).
Barry, E. R. et al. Restriction of intestinal stem cell enlargement and the regenerative response by YAP. Nature 493, 106–110 (2013).
Gregorieff, A., Liu, Y., Inanlou, M. R., Khomchuk, Y. & Wrana, J. L. Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and most cancers. Nature 526, 715–718 (2015).
Yui, S. et al. YAP/TAZ-dependent reprogramming of colonic epithelium hyperlinks ECM transforming to tissue regeneration. Cell Stem Cell 22, 35–49.e7 (2018).
Ohara, T. E., Colonna, M. & Stappenbeck, T. S. Adaptive differentiation promotes intestinal villus restoration. Dev. Cell 57, 166–179.e6 (2022).
Nusse, Y. M. et al. Parasitic helminths induce fetal-like reversion within the intestinal stem cell area of interest. Nature 559, 109–113 (2018).
Pikkupeura, L. M. et al. Transcriptional and epigenomic profiling identifies YAP signaling as a key regulator of intestinal epithelium maturation. Sci. Adv. 9, eadf9460 (2023).
Guiu, J. et al. Tracing the origin of grownup intestinal stem cells. Nature 570, 107–111 (2019).
Mustata, R. C. et al. Identification of Lgr5-independent spheroid-generating progenitors of the mouse fetal intestinal epithelium. Cell Rep. 5, 421–432 (2013).
Ohta, Y. et al. Cell-matrix interface regulates dormancy in human colon most cancers stem cells. Nature 608, 784–794 (2022).
Solé, L. et al. P53 wild-type colorectal most cancers cells that categorical a fetal gene signature are related to metastasis and poor prognosis. Nat. Commun. 13, 2866 (2022).
Lupo, B. et al. Colorectal most cancers residual illness at maximal response to EGFR blockade shows a druggable Paneth cell-like phenotype. Sci. Transl. Med. 12, eaax8313 (2020).
Leach, J. D. G. et al. Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis. Nat. Commun. 12, 3464 (2021).
Martinez-Ordoñez, A. et al. Hyaluronan pushed by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal most cancers. Most cancers Cell 41, 252–271.e9 (2023).
Vasquez, E. G. et al. Dynamic and adaptive most cancers stem cell inhabitants admixture in colorectal neoplasia. Cell Stem Cell 29, 1213–1228.e8 (2022).
Ramos Zapatero, M. et al. Trellis tree-based evaluation reveals stromal regulation of patient-derived organoid drug responses. Cell 186, 5606–5619.e24 (2023).
Moorman, A. R. et al. Progressive plasticity throughout colorectal most cancers metastasis. Preprint at bioRxiv https://doi.org/10.1101/2023.08.18.553925 (2023).
Qin, X. et al. An oncogenic phenoscape of colonic stem cell polarization. Cell 186, 5554–5568.e18 (2023).
Azzolin, L. et al. YAP/TAZ incorporation within the β-catenin destruction complicated orchestrates the Wnt response. Cell 158, 157–170 (2014).
Cheung, P. et al. Regenerative reprogramming of the intestinal stem cell state through Hippo signaling suppresses metastatic colorectal most cancers. Cell Stem Cell 27, 590–604.e9 (2020).
Latacz, E. et al. Histopathological development patterns of liver metastasis: up to date consensus pointers for sample scoring, views and up to date mechanistic insights. Br. J. Most cancers 127, 988–1013 (2022).
Frentzas, S. et al. Vessel co-option mediates resistance to anti-angiogenic remedy in liver metastases. Nat. Med. 22, 1294–1302 (2016).
Nierop, P. M. H. et al. Preoperative systemic chemotherapy alters the histopathological development patterns of colorectal liver metastases. J. Pathol. Clin. Res. 8, 48–64 (2022).
Rubbia-Brandt, L. et al. Significance of histological tumor response evaluation in predicting the result in sufferers with colorectal liver metastases handled with neo-adjuvant chemotherapy adopted by liver surgical procedure. Ann. Oncol. 18, 299–304 (2007).
Messaoudi, N. et al. Prognostic implications of adaptive immune options in MMR-proficient colorectal liver metastases labeled by histopathological development patterns. Br. J. Most cancers 126, 1329–1338 (2022).
Stremitzer, S. et al. Immune phenotype and histopathological development sample in sufferers with colorectal liver metastases. Br. J. Most cancers 122, 1518–1524 (2020).
Liang, J. Y. et al. Histopathological development patterns correlate with the immunoscore in colorectal most cancers liver metastasis sufferers after hepatectomy. Most cancers Immunol. Immunother. 69, 2623–2634 (2020).
Chen, D. S. & Mellman, I. Parts of most cancers immunity and the cancer-immune set level. Nature 541, 321–330 (2017).
Liu, Y. et al. Immune phenotypic linkage between colorectal most cancers and liver metastasis. Most cancers Cell 40, 424–437.e5 (2022).
Che, L. H. et al. A single-cell atlas of liver metastases of colorectal most cancers reveals reprogramming of the tumor microenvironment in response to preoperative chemotherapy. Cell Discov. 7, 80 (2021).
Wang, F. et al. Single-cell and spatial transcriptome evaluation reveals the mobile heterogeneity of liver metastatic colorectal most cancers. Sci. Adv. 9, eadf5464 (2023).
Friedman, E. et al. Excessive ranges of remodeling development issue beta 1 correlate with illness development in human colon most cancers. Most cancers Epidemiol. Biomark. Prev. 4, 549–554 (1995).
Calon, A. et al. Dependency of colorectal most cancers on a TGF-β-driven program in stromal cells for metastasis initiation. Most cancers Cell 22, 571–584 (2012).
Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal most cancers. Nat. Genet. 47, 320–329 (2015).
Kalluri, R. The biology and performance of fibroblasts in most cancers. Nat. Rev. Most cancers 16, 582–598 (2016).
Mariathasan, S. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
Chakravarthy, A., Khan, L., Bensler, N. P., Bose, P. & De Carvalho, D. D. TGF-β-associated extracellular matrix genes hyperlink cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat. Commun. 9, 4692 (2018).
Tauriello, D. V. F., Sancho, E. & Batlle, E. Overcoming TGFβ-mediated immune evasion in most cancers. Nat. Rev. Most cancers 22, 25–44 (2022).
Krishnamurty, A. T. et al. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature 611, 148–154 (2022).
Nicolas-Boluda, A. & Donnadieu, E. Obstacles to T cell migration within the tumor microenvironment. Comp. Immunol. Microbiol. Infect. Dis. 63, 22–30 (2019).
Wolf, Ok., Müller, R., Borgmann, S., Bröcker, E.-B. & Friedl, P. Amoeboid form change and call steerage: T-lymphocyte crawling by fibrillar collagen is impartial of matrix transforming by MMPs and different proteases. Blood 102, 3262–3269 (2003).
Kaur, A. et al. Reworking of the collagen matrix in growing older pores and skin promotes melanoma metastasis and impacts immune cell motility. Most cancers Discov. 9, 64–81 (2019).
Salmon, H. et al. Matrix structure defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Make investments. 122, 899–910 (2012).
Sadjadi, Z., Zhao, R., Hoth, M., Qu, B. & Rieger, H. Migration of cytotoxic T lymphocytes in 3D collagen matrices. Biophys. J. 119, 2141–2152 (2020).
Shen, Y. et al. Discount of liver metastasis stiffness improves response to bevacizumab in metastatic colorectal most cancers. Most cancers Cell 37, 800–817.e7 (2020).
Friedl, P. & Gilmour, D. Collective cell migration in morphogenesis, regeneration and most cancers. Nat. Rev. Mol. Cell Biol. 10, 445–457 (2009).
Linares, J. et al. Lengthy-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal most cancers development and resistance to remedy. Nat. Commun. 14, 746 (2023).
Li, H. et al. Reference part evaluation of single-cell transcriptomes elucidates mobile heterogeneity in human colorectal tumors. Nat. Genet. 49, 708–718 (2017).
Lee, H. O. et al. Lineage-dependent gene expression applications affect the immune panorama of colorectal most cancers. Nat. Genet. 52, 594–603 (2020).
Kobayashi, H. et al. The origin and contribution of cancer-associated fibroblasts in colorectal carcinogenesis. Gastroenterology 162, 890–906 (2022).
Heichler, C. et al. STAT3 activation by IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour improvement and correlates with poor prognosis. Intestine 69, 1269–1282 (2020).
Koncina, E. et al. IL1R1+ cancer-associated fibroblasts drive tumor improvement and immunosuppression in colorectal most cancers. Nat. Commun. 14, 4251 (2023).
Kobayashi, H. et al. The steadiness of stromal BMP signaling mediated by GREM1 and ISLR drives colorectal carcinogenesis. Gastroenterology 160, 1224–1239.e30 (2021).
Khaliq, A. M. et al. Refining colorectal most cancers classification and scientific stratification by a single-cell atlas. Genome Biol. 23, 113 (2022).
Nicolas, A. M. et al. Inflammatory fibroblasts mediate resistance to neoadjuvant remedy in rectal most cancers. Most cancers Cell 40, 168–184.e13 (2022).
Bhattacharjee, S. et al. Tumor restriction by sort I collagen opposes tumor-promoting results of cancer-associated fibroblasts. J. Clin. Make investments. 131, e146987 (2021).
Hu, X. et al. Prediction of hepatic metastasis and relapse in colorectal cancers primarily based on concordance analyses with liver fibrosis scores. Clin. Transl. Med. 9, e13 (2020).
Schumacher, T. N. & Schreiber, R. D. Neoantigens in most cancers immunotherapy. Science 348, 69–74 (2015).
Dolcetti, R. et al. Excessive prevalence of activated intraepithelial cytotoxic T lymphocytes and elevated neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am. J. Pathol. 154, 1805–1813 (1999).
Popat, S., Hubner, R. & Houlston, R. S. Systematic assessment of microsatellite instability and colorectal most cancers prognosis. J. Clin. Oncol. 23, 609–618 (2005).
Pelka, Ok. et al. Spatially organized multicellular immune hubs in human colorectal most cancers. Cell 184, 4734–4752.e20 (2021).
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
Le, D. T. et al. Mismatch restore deficiency predicts response of strong tumors to PD-1 blockade. Science 357, 409–413 (2017).
Overman, M. J. et al. Nivolumab in sufferers with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal most cancers (CheckMate 142): an open-label, multicentre, part 2 examine. Lancet Oncol. 18, 1182–1191 (2017).
André, T. et al. Pembrolizumab in microsatellite-instability-high superior colorectal most cancers. N. Engl. J. Med. 383, 2207–2218 (2020).
Chalabi, M. et al. Neoadjuvant immunotherapy results in pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566–576 (2020).
Chalabi, M. et al. Neoadjuvant immune checkpoint inhibition in regionally superior MMR-deficient colon most cancers: the NICHE-2 examine [abstract LBA7]. Ann. Oncol. 33 (Suppl. 7), S1389 (2022).
Cercek, A. et al. PD-1 blockade in mismatch restore–poor, regionally superior rectal most cancers. N. Engl. J. Med. 386, 2363–2376 (2022).
Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response charge to PD-1 inhibition. N. Engl. J. Med. 377, 2500–2501 (2017).
Galon, J. J. et al. Sort, density, and site of immune cells inside human colorectal tumors predict scientific consequence. Science 313, 1960–1964 (2006).
Pagès, F. et al. Worldwide validation of the consensus Immunoscore for the classification of colon most cancers: a prognostic and accuracy examine. Lancet 391, 2128–2139 (2018).
Pagès, F. et al. Effector reminiscence T cells, early metastasis, and survival in colorectal most cancers. N. Engl. J. Med. 353, 2654–2666 (2005).
Mlecnik, B. et al. The tumor microenvironment and Immunoscore are crucial determinants of dissemination to distant metastasis. Sci. Transl. Med. 8, 327ra26 (2016).
Berghoff, A. S. et al. Density of tumor-infiltrating lymphocytes correlates with extent of mind edema and general survival time in sufferers with mind metastases. Oncoimmunology 5, e1057388 (2016).
Mlecnik, B. et al. Integrative analyses of colorectal most cancers present Immunoscore is a stronger predictor of affected person survival than microsatellite instability. Immunity 44, 698–711 (2016).
Hurtado, C. G., Wan, F., Housseau, F. & Sears, C. L. Roles for interleukin 17 and adaptive immunity in pathogenesis of colorectal most cancers. Gastroenterology 155, 1706–1715 (2018).
Van den Eynde, M. et al. The hyperlink between the multiverse of immune microenvironments in metastases and the survival of colorectal most cancers sufferers. Most cancers Cell 34, 1012–1026.e3 (2018).
Angelova, M. et al. Evolution of metastases in area and time beneath immune choice. Cell 175, 751–765.e16 (2018).
Crisafulli, G. et al. Temozolomide remedy alters mismatch restore and boosts mutational burden in tumor and blood of colorectal most cancers sufferers. Most cancers Discov. 12, 1656–1675 (2022).
Amodio, V. et al. Genetic and pharmacological modulation of DNA mismatch restore heterogeneous tumors promotes immune surveillance. Most cancers Cell 41, 196–209.e5 (2023).
Zhang, L. et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon most cancers. Cell 181, 442–459.e29 (2020).
Revel, M., Sautès-Fridman, C., Fridman, W.-H. & Roumenina, L. T. C1q+ macrophages: passengers or drivers of most cancers development. Developments Most cancers 8, 517–526 (2022).
Sathe, A. et al. Colorectal most cancers metastases within the liver set up immunosuppressive spatial networking between tumor-associated SPP1+ macrophages and fibroblasts. Clin. Most cancers Res. 29, 244–260 (2023).
Qi, J. et al. Single-cell and spatial evaluation reveal interplay of FAP+ fibroblasts and SPP1+ macrophages in colorectal most cancers. Nat. Commun. 13, 1742 (2022).
Ozato, Y. et al. Spatial and single-cell transcriptomics decipher the mobile atmosphere containing HLA-G+ most cancers cells and SPP1+ macrophages in colorectal most cancers. Cell Rep. 42, 111929 (2023).
Ries, C. H. et al. Focusing on tumor-associated macrophages with anti-CSF-1R antibody reveals a method for most cancers remedy. Most cancers Cell 25, 846–859 (2014).
Zheng, W. et al. Tumor-associated neutrophils in colorectal most cancers improvement, development and immunotherapy. Cancers 14, 4755 (2022).
Singhal, S. et al. Origin and function of a subset of tumor-associated neutrophils with antigen-presenting cell options in early-stage human lung most cancers. Most cancers Cell 30, 120–135 (2016).
Jaillon, S. et al. Neutrophil range and plasticity in tumour development and remedy. Nat. Rev. Most cancers 20, 485–503 (2020).
Ogawa, R. et al. Lack of Smad4 promotes colorectal most cancers development by recruiting tumor-associated neutrophils through the CXCL1/8–CXCR2 axis. Clin. Most cancers Res. 25, 2887–2899 (2019).
Yamamoto, T. et al. Lack of SMAD4 promotes lung metastasis of colorectal most cancers by accumulation of CCR1+ tumor-associated neutrophils by CCL15-CCR1 axis. Clin. Most cancers Res. 23, 833–844 (2017).
Jackstadt, R. et al. Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal most cancers to drive poor-prognosis subtypes and metastasis. Most cancers Cell 36, 319–336.e7 (2019).
Lepsenyi, M. et al. CXCL2-CXCR2 axis mediates αV integrin-dependent peritoneal metastasis of colon most cancers cells. Clin. Exp. Metastasis 38, 401–410 (2021).
Liao, W. et al. KRAS-IRF2 axis drives immune suppression and immune remedy resistance in colorectal most cancers. Most cancers Cell 35, 559–572.e7 (2019).
Germann, M. et al. Neutrophils suppress tumor‐infiltrating T cells in colon most cancers through matrix metalloproteinase‐mediated activation of TGFβ. EMBO Mol. Med. 12, e10681 (2020).
Tian, S. et al. Tumour-associated neutrophils secrete AGR2 to advertise colorectal most cancers metastasis through its receptor CD98hc–xCT. Intestine 71, 2489–2501 (2022).
Itatani, Y. et al. Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic mannequin of colorectal most cancers. Proc. Natl Acad. Sci. USA 117, 21598–21608 (2020).
Albrengues, J. et al. Neutrophil extracellular traps produced throughout irritation awaken dormant most cancers cells in mice. Science 361, eaao4227 (2018).
Yahagi, M. et al. Smoking is a danger issue for pulmonary metastasis in colorectal most cancers. Colorectal Dis. 19, O322–O328 (2017).
Bertocchi, A. et al. Intestine vascular barrier impairment results in intestinal micro organism dissemination and colorectal most cancers metastasis to liver. Most cancers Cell 39, 708–724.e11 (2021).
Peuker, Ok. et al. Epithelial calcineurin controls microbiota-dependent intestinal tumor improvement. Nat. Med. 22, 506–515 (2016).
Routy, B. et al. Intestine microbiome influences efficacy of PD-1-based immunotherapy in opposition to epithelial tumors. Science 359, 91–97 (2018).
Yachida, S. et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the intestine microbiota in colorectal most cancers. Nat. Med. 25, 968–976 (2019).
Roelands, J. et al. An built-in tumor, immune and microbiome atlas of colon most cancers. Nat. Med. 29, 1273–1286 (2023).
Peuker, Ok. et al. Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal most cancers. Immunity 55, 701–717.e7 (2022).
Sahin, I. H., Ciombor, Ok. Ok., Diaz, L. A., Yu, J. & Kim, R. Immunotherapy for microsatellite secure colorectal cancers: challenges and novel therapeutic avenues. Am. Soc. Clin. Oncol. Educ. E book. 42, 242–253 (2022).
Fukuoka, S. et al. Regorafenib plus nivolumab in sufferers with superior gastric or colorectal most cancers: an open-label, dose-escalation, and dose-expansion part Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 38, 2053–2061 (2020).
Fakih, M. et al. Immunotherapy response in microsatellite secure metastatic colorectal most cancers is influenced by website of metastases. Eur. J. Most cancers 196, 113437 (2024).
Chen, E. X. et al. Liver metastases and immune checkpoint inhibitor efficacy in sufferers with refractory metastatic colorectal most cancers: a secondary evaluation of a randomized scientific trial. JAMA Netw. Open. 6, e2346094 (2023).
Yu, J. et al. Liver metastasis restrains immunotherapy efficacy through macrophage-mediated T cell elimination. Nat. Med. 27, 152–164 (2021).
Lee, J. C. et al. Regulatory T cell management of systemic immunity and immunotherapy response in liver metastasis. Sci. Immunol. 5, eaba0759 (2020).
Bando, H., Ohtsu, A. & Yoshino, T. Therapeutic panorama and future course of metastatic colorectal most cancers. Nat. Rev. Gastroenterol. Hepatol. 20, 306–322 (2023).
Lote, H., Starling, N., Pihlak, R. & Gerlinger, M. Advances in immunotherapy for MMR proficient colorectal most cancers. Most cancers Deal with. Rev. 111, 102480 (2022).
Martins, F. et al. Hostile results of immune-checkpoint inhibitors: epidemiology, administration and surveillance. Nat. Rev. Clin. Oncol. 16, 563–580 (2019).
Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts scientific outcomes in resectable melanoma. Nat. Med. 25, 454–461 (2019).
Derksen, J. W. G. et al. The Potential Dutch Colorectal Most cancers (PLCRC) cohort: real-world information facilitating analysis and scientific care. Sci. Rep. 11, 3923 (2021).
Meguid, R. A., Slidell, M. B., Wolfgang, C. L., Chang, D. C. & Ahuja, N. Is there a distinction in survival between right- versus left-sided colon cancers? Ann. Surg. Oncol. 15, 2388–2394 (2008).
Alese, O. B. et al. Predictive and prognostic results of major tumor measurement on colorectal most cancers survival. Entrance. Oncol. 11, 728076 (2021).
Liu, Y. et al. Comparative molecular evaluation of gastrointestinal adenocarcinomas. Most cancers Cell 33, 721–735.e8 (2018).
Seshagiri, S. et al. Recurrent R-spondin fusions in colon most cancers. Nature 488, 660–664 (2012).
Birgin, E. et al. Prognostic worth of disease-free interval in colorectal most cancers: is it time? Eur. J. Surg. Oncol. 48, 2032–2038 (2022).
Väyrynen, V. et al. Incidence and administration of sufferers with colorectal most cancers and synchronous and metachronous colorectal metastases: a population-based examine. BJS Open. 4, 685–692 (2020).
Hugen, N., van de Velde, C. J. H., de Wilt, J. H. W. & Nagtegaal, I. D. Metastatic sample in colorectal most cancers is strongly influenced by histological subtype. Ann. Oncol. 25, 651–657 (2014).
De Sousa E Melo, F. et al. Poor-prognosis colon most cancers is outlined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 19, 614–618 (2013).
Marisa, L. et al. Gene expression classification of colon most cancers into molecular subtypes: characterization, validation, and prognostic worth. PLoS Med. 10, e1001453 (2013).
Sadanandam, A. et al. A colorectal most cancers classification system that associates mobile phenotype and responses to remedy. Nat. Med. 19, 619–625 (2013).
Isella, C. et al. Stromal contribution to the colorectal most cancers transcriptome. Nat. Genet. 47, 312–319 (2015).
Guinney, J. et al. The consensus molecular subtypes of colorectal most cancers. Nat. Med. 21, 1350–1356 (2015).
Piskol, R. et al. A clinically relevant gene-expression classifier reveals intrinsic and extrinsic contributions to consensus molecular subtypes in major and metastatic colon most cancers. Clin. Most cancers Res. 25, 4431–4442 (2019).
Eide, P. W. et al. Metastatic heterogeneity of the consensus molecular subtypes of colorectal most cancers. NPJ Genom. Med. 6, 59 (2021).
Moosavi, S. H. et al. De novo transcriptomic subtyping of colorectal most cancers liver metastases within the context of tumor heterogeneity. Genome Med. 13, 143 (2021).
Gengenbacher, N., Singhal, M. & Augustin, H. G. Preclinical mouse strong tumour fashions: established order, challenges and views. Nat. Rev. Most cancers 17, 751–765 (2017).
Jackstadt, R. & Sansom, O. J. Mouse fashions of intestinal most cancers. J. Pathol. 238, 141–151 (2016).
Amirkhah, R. et al. MmCMS: mouse fashions’ consensus molecular subtypes of colorectal most cancers. Br. J. Most cancers 128, 1333–1343 (2023).
Fumagalli, A. et al. A surgical orthotopic organoid transplantation strategy in mice to visualise and examine colorectal most cancers development. Nat. Protoc. 13, 235–247 (2018).
Nguyen, T. L. A., Vieira-Silva, S., Liston, A. & Raes, J. How informative is the mouse for human intestine microbiota analysis? Dis. Mannequin. Mech. 8, 1–16 (2015).
